VVOS (Vivos Therapeutics, Inc.) Bathi resik

Vivos Therapeutics is developing a network of partnerships with private dental practices to implement non-invasive apnea therapy. The company's net income confirms this trajectory, where -0.03 serves as the final level mark. The issuer is scaling innovative airway correction devices, although global trade barriers and overseas certification complexities create certain risks for international expansion.

The expansion of insurance coverage for dental sleep apnea treatment systems directly impacts the profit trajectory of Vivos Therapeutics (VVOS), activating operating leverage as sales volumes grow. This price action reflects the variance between total revenues and expenses, where the curve's extremes define the boundaries of fundamental value and signal either peaks in efficiency or deep crises, warning investors of potential drawdown risks.